{"id":41338,"date":"2024-04-04T13:06:19","date_gmt":"2024-04-04T13:06:19","guid":{"rendered":"https:\/\/conseil-concurrence.preprod.io\/communique-du-conseil-de-la-concurrence-relatif-au-projet-de-concentration-qui-concerne-la-prise-du-controle-exclusif-des-societes-kelix-bio-limited-gulf-inject-llc-2\/"},"modified":"2026-02-06T12:47:03","modified_gmt":"2026-02-06T12:47:03","slug":"press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc","status":"publish","type":"post","link":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/","title":{"rendered":"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d"},"content":{"rendered":"<p>In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties.<\/p>\n<p>This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation.<\/p>\n<p>The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition.<\/p>\n<p><strong>Names of the companies and groups concerned:<\/strong><\/p>\n<ul>\n<li><strong>The acquirer<\/strong>: <strong>\u201c<\/strong>Mubadala Investment Company<strong>\u201d<\/strong>;<\/li>\n<li><strong>The targets<\/strong>:\n<ul>\n<li><strong>\u201c<\/strong>Kelix Bio Limited<strong>\u201d<\/strong>;<\/li>\n<li><strong>\u201c<\/strong>Gulf Inject LLC<strong>\u201d<\/strong>;<\/li>\n<li><strong>\u201c<\/strong>Bioventure FZ LLC<strong>\u201d<\/strong>;<\/li>\n<li><strong>\u201c<\/strong>Bioventure Healthcare FZE<strong>\u201d<\/strong>;<\/li>\n<li><strong>\u201c<\/strong>Wellpharma Medical Solutions<strong>\u201d<\/strong>;<\/li>\n<li><strong>\u201c<\/strong>Diabtec LLC<strong>\u201d<\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Nature of the operation<\/strong><\/p>\n<ul>\n<li>Exclusive takeover.<\/li>\n<\/ul>\n<p><strong>Economic sectors concerned<\/strong><\/p>\n<ul>\n<li>The market for the development, production, and distribution of medicines.<\/li>\n<\/ul>\n<p><strong>Deadline for interested third parties to submit their observations<\/strong><\/p>\n<p>&#8211; 10 days from the date of publication of this press release, i.e., April 15, 2024.<\/p>\n<p><strong>NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n<p>The Competition Council received notification of an economic concentration operation concerning the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d by the company \u201cMubadala Investment Company\u201d.<\/p>\n<p>The proposed operation involves the acquisition by the company \u201cMubadala Investment Company PJSC\u201d, through its subsidiary \u201cMIC UAE Investments 1 RSC Limited\u201d, of 100% of the shares of the company \u201cKelix Bio Limited\u201d. Following this acquisition, \u201cKelix\u201d (through a wholly-owned subsidiary) intends to acquire 100% of the shares of the companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d.<\/p>\n<p>\u201cMIC UAE\u201d is a 100% indirect subsidiary of the company \u201cMubadala\u201d, established in the Emirate of Abu Dhabi. \u201cMubadala\u201d invests in a wide range of private and listed asset categories.<\/p>\n<p>\u201cKelix\u201d is a British biopharmaceutical company active in emerging markets and based in the UAE, targeting significant, rapidly growing, and differentiated therapeutic areas through innovation and cost-effectiveness. It focuses on therapeutic areas and product forms with high demand and growth potential, such as oncology, diabetes, respiratory diseases, inhalers, injectable products, and biosimilars.<\/p>\n<p>The companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d are UAE-based companies operating in the health and pharmaceutical sectors.<\/p>\n<p style=\"text-align: right;\">Done in Rabat on April 4, 2024.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition. Names of the companies and groups concerned: The acquirer: \u201cMubadala Investment Company\u201d; The targets: \u201cKelix Bio Limited\u201d; \u201cGulf Inject LLC\u201d; \u201cBioventure FZ LLC\u201d; \u201cBioventure Healthcare FZE\u201d; \u201cWellpharma Medical Solutions\u201d; \u201cDiabtec LLC\u201d. Nature of the operation Exclusive takeover. Economic sectors concerned The market for the development, production, and distribution of medicines. Deadline for interested third parties to submit their observations &#8211; 10 days from the date of publication of this press release, i.e., April 15, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d by the company \u201cMubadala Investment Company\u201d. The proposed operation involves the acquisition by the company \u201cMubadala Investment Company PJSC\u201d, through its subsidiary \u201cMIC UAE Investments 1 RSC Limited\u201d, of 100% of the shares of the company \u201cKelix Bio Limited\u201d. Following this acquisition, \u201cKelix\u201d (through a wholly-owned subsidiary) intends to acquire 100% of the shares of the companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d. \u201cMIC UAE\u201d is a 100% indirect subsidiary of the company \u201cMubadala\u201d, established in the Emirate of Abu Dhabi. \u201cMubadala\u201d invests in a wide range of private and listed asset categories. \u201cKelix\u201d is a British biopharmaceutical company active in emerging markets and based in the UAE, targeting significant, rapidly growing, and differentiated therapeutic areas through innovation and cost-effectiveness. It focuses on therapeutic areas and product forms with high demand and growth potential, such as oncology, diabetes, respiratory diseases, inhalers, injectable products, and biosimilars. The companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d are UAE-based companies operating in the health and pharmaceutical sectors. Done in Rabat on April 4, 2024.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-41338","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d - Conseil de la concurrence du Maroc<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d - Conseil de la concurrence du Maroc\" \/>\n<meta property=\"og:description\" content=\"In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition. Names of the companies and groups concerned: The acquirer: \u201cMubadala Investment Company\u201d; The targets: \u201cKelix Bio Limited\u201d; \u201cGulf Inject LLC\u201d; \u201cBioventure FZ LLC\u201d; \u201cBioventure Healthcare FZE\u201d; \u201cWellpharma Medical Solutions\u201d; \u201cDiabtec LLC\u201d. Nature of the operation Exclusive takeover. Economic sectors concerned The market for the development, production, and distribution of medicines. Deadline for interested third parties to submit their observations &#8211; 10 days from the date of publication of this press release, i.e., April 15, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d by the company \u201cMubadala Investment Company\u201d. The proposed operation involves the acquisition by the company \u201cMubadala Investment Company PJSC\u201d, through its subsidiary \u201cMIC UAE Investments 1 RSC Limited\u201d, of 100% of the shares of the company \u201cKelix Bio Limited\u201d. Following this acquisition, \u201cKelix\u201d (through a wholly-owned subsidiary) intends to acquire 100% of the shares of the companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d. \u201cMIC UAE\u201d is a 100% indirect subsidiary of the company \u201cMubadala\u201d, established in the Emirate of Abu Dhabi. \u201cMubadala\u201d invests in a wide range of private and listed asset categories. \u201cKelix\u201d is a British biopharmaceutical company active in emerging markets and based in the UAE, targeting significant, rapidly growing, and differentiated therapeutic areas through innovation and cost-effectiveness. It focuses on therapeutic areas and product forms with high demand and growth potential, such as oncology, diabetes, respiratory diseases, inhalers, injectable products, and biosimilars. The companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d are UAE-based companies operating in the health and pharmaceutical sectors. Done in Rabat on April 4, 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/\" \/>\n<meta property=\"og:site_name\" content=\"Conseil de la concurrence du Maroc\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-04T13:06:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T12:47:03+00:00\" \/>\n<meta name=\"author\" content=\"Youssef OTMANE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Youssef OTMANE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/\"},\"author\":{\"name\":\"Youssef OTMANE\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\"},\"headline\":\"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d\",\"datePublished\":\"2024-04-04T13:06:19+00:00\",\"dateModified\":\"2026-02-06T12:47:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/\"},\"wordCount\":462,\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/\",\"name\":\"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d - Conseil de la concurrence du Maroc\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#website\"},\"datePublished\":\"2024-04-04T13:06:19+00:00\",\"dateModified\":\"2026-02-06T12:47:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\",\"name\":\"Conseil de la concurrence du Maroc\",\"description\":\"Conseil de la concurrence\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\",\"name\":\"Youssef OTMANE\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d - Conseil de la concurrence du Maroc","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/","og_locale":"en_US","og_type":"article","og_title":"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d - Conseil de la concurrence du Maroc","og_description":"In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition. Names of the companies and groups concerned: The acquirer: \u201cMubadala Investment Company\u201d; The targets: \u201cKelix Bio Limited\u201d; \u201cGulf Inject LLC\u201d; \u201cBioventure FZ LLC\u201d; \u201cBioventure Healthcare FZE\u201d; \u201cWellpharma Medical Solutions\u201d; \u201cDiabtec LLC\u201d. Nature of the operation Exclusive takeover. Economic sectors concerned The market for the development, production, and distribution of medicines. Deadline for interested third parties to submit their observations &#8211; 10 days from the date of publication of this press release, i.e., April 15, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d by the company \u201cMubadala Investment Company\u201d. The proposed operation involves the acquisition by the company \u201cMubadala Investment Company PJSC\u201d, through its subsidiary \u201cMIC UAE Investments 1 RSC Limited\u201d, of 100% of the shares of the company \u201cKelix Bio Limited\u201d. Following this acquisition, \u201cKelix\u201d (through a wholly-owned subsidiary) intends to acquire 100% of the shares of the companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d. \u201cMIC UAE\u201d is a 100% indirect subsidiary of the company \u201cMubadala\u201d, established in the Emirate of Abu Dhabi. \u201cMubadala\u201d invests in a wide range of private and listed asset categories. \u201cKelix\u201d is a British biopharmaceutical company active in emerging markets and based in the UAE, targeting significant, rapidly growing, and differentiated therapeutic areas through innovation and cost-effectiveness. It focuses on therapeutic areas and product forms with high demand and growth potential, such as oncology, diabetes, respiratory diseases, inhalers, injectable products, and biosimilars. The companies \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellPharma Medical Solutions\u201d, and \u201cDiabtec LLC\u201d are UAE-based companies operating in the health and pharmaceutical sectors. Done in Rabat on April 4, 2024.","og_url":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/","og_site_name":"Conseil de la concurrence du Maroc","article_published_time":"2024-04-04T13:06:19+00:00","article_modified_time":"2026-02-06T12:47:03+00:00","author":"Youssef OTMANE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Youssef OTMANE","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/#article","isPartOf":{"@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/"},"author":{"name":"Youssef OTMANE","@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81"},"headline":"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d","datePublished":"2024-04-04T13:06:19+00:00","dateModified":"2026-02-06T12:47:03+00:00","mainEntityOfPage":{"@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/"},"wordCount":462,"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/","url":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/","name":"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d - Conseil de la concurrence du Maroc","isPartOf":{"@id":"https:\/\/conseil-concurrence.ma\/en\/#website"},"datePublished":"2024-04-04T13:06:19+00:00","dateModified":"2026-02-06T12:47:03+00:00","author":{"@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81"},"breadcrumb":{"@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-concentration-project-involving-the-exclusive-takeover-of-the-companies-kelix-bio-limited-gulf-inject-llc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/conseil-concurrence.ma\/en\/"},{"@type":"ListItem","position":2,"name":"Press Release from the Competition Council regarding the concentration project involving the exclusive takeover of the companies \u201cKelix Bio Limited\u201d, \u201cGulf Inject LLC\u201d, \u201cBioventure FZ LLC\u201d, \u201cBioventure Healthcare FZE\u201d, \u201cWellpharma Medical Solutions\u201d, and \u201cDiabtec LLC,\u201d by the company \u201cMubadala Investment Company\u201d"}]},{"@type":"WebSite","@id":"https:\/\/conseil-concurrence.ma\/en\/#website","url":"https:\/\/conseil-concurrence.ma\/en\/","name":"Conseil de la concurrence du Maroc","description":"Conseil de la concurrence","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/conseil-concurrence.ma\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81","name":"Youssef OTMANE","url":"https:\/\/conseil-concurrence.ma\/en\/"}]}},"_links":{"self":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/comments?post=41338"}],"version-history":[{"count":1,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41338\/revisions"}],"predecessor-version":[{"id":45110,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41338\/revisions\/45110"}],"wp:attachment":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/media?parent=41338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/categories?post=41338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/tags?post=41338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}